Reviving Decades-Old Wisdom: Longitudinal Analysis of Renin–Angiotensin System Inhibitors and Its Effects on Acute Ischemic Stroke to Improve Outcomes
American Journal of Hypertension · 2024
DOI: 10.1093/ajh/hpae033 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hypertension, 2024. Verfasst von Sophie Samuel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Memorial Hermann Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: Renin-Angiotensin System, Ischemic Stroke, Angiotensin-Converting Enzyme Inhibitors, Hospital Mortality. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND While renin–angiotensin system (RAS) inhibitors have a longstanding history in blood pressure control, their suitability as first-line in-patient treatment may be limited due to prolonged half-life and kidney failure concerns. METHODS Using a cohort design, we assessed the impact of RAS inhibitors, either alone or in combination with beta-blockers, on mortality, while exploring interactions, including those related to end-stage renal disease and serum creatinine levels. Eligible subjects were Acute Ischemic Stroke (AIS) patients aged 18 or older with specific subtypes who received in-patient antihypertensive treatment. The primary outcome was mortality rates. Statistical analyses included cross-sectional and longitudinal approaches, employing generalized linear models, G-computation, and discrete-time survival analysis over a 20-day follow-up period. RESULTS In our study of 3,058 AIS patients, those using RAS inhibitors had significantly lower in-hospital mortality (2.2%) compared to non-users (12.1%), resulting in a relative risk (RR) of 0.18 (95% CI: 0.12–0.26). Further analysis using G-computation revealed a marked reduction in mortality risk associated with RAS inhibitors (0.0281 vs. 0.0913, risk difference [RD] of 6.31% or 0.0631, 95% CI: 0.046–0.079). Subgroup analysis demonstrated notable benefits, with individuals having creatinine levels below and above 1.3 mg/dl exhibiting statistically significant RD (RD −0.0510 vs. −0.0895), and a significant difference in paired comparison (−0.0385 or 3.85%, CI 0.023–0.054). Additionally, longitudinal analysis confirmed a consistent daily reduction of 0.93% in mortality risk associated with the intake of RAS inhibitors. CONCLUSIONS RAS inhibitors are associated with a significant reduction in in-hospital mortality in AIS patients, suggesting potential clinical benefits in improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Memorial Hermann Hospital, Houston, Texas, USA.
- Institute of Clinical Research and Learning Health Care, UT Health Houston, Houston, Texas, USA.
- Department of Neurology, McGovern Medical School, UT Health Houston, Houston, Texas, USA.
- Department of Neurosurgery, McGovern Medical School, UT Health Houston, Houston, Texas, USA.
ORCID-Profile: Sophie Samuel
Zitieren
APA
Samuel, S., Craver, K., Miller, C., Pelsue, B., Gonzalez, C., Allison, T. A., Gulbis, B., Choi, H. A., & Kim, S. (2024). Reviving Decades-Old Wisdom: Longitudinal Analysis of Renin–Angiotensin System Inhibitors and Its Effects on Acute Ischemic Stroke to Improve Outcomes. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpae033
Vancouver
Samuel S, Craver K, Miller C, Pelsue B, Gonzalez C, Allison TA, et al. Reviving Decades-Old Wisdom: Longitudinal Analysis of Renin–Angiotensin System Inhibitors and Its Effects on Acute Ischemic Stroke to Improve Outcomes. American Journal of Hypertension. 2024. doi:10.1093/ajh/hpae033
BibTeX
@article{Samuel2024,
author = {Samuel, Sophie and Craver, Kyndol and Miller, Charles and Pelsue, Brittany and Gonzalez, Catherine and Allison, Teresa A and Gulbis, Brian and Choi, Huimahn Alex and Kim, Seokhun},
title = {Reviving Decades-Old Wisdom: Longitudinal Analysis of Renin–Angiotensin System Inhibitors and Its Effects on Acute Ischemic Stroke to Improve Outcomes},
journal = {American Journal of Hypertension},
year = {2024},
doi = {10.1093/ajh/hpae033}
}
EUVIMED